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Background
The canarypox vector ALVAC-HIV, together with the
HIV gp120 envelope, has protected 31.2% of Thai hetero-
sexual individuals from HIV acquisition in the RV144 HIV
vaccine trial. This outcome was unexpected, given the lim-
ited ability of the ALVAC-HIV vaccine component to
induce CD8+T-cell responses, and of the HIVgp120 envel-
ope to elicit broad neutralizing antibodies.
Methods
We vaccinated macaques with an immunization regimen
that mimics the RV144 trial and exposed them to a muco-
sal dose of SIVmac251 that transmits few virus variants,
similar to HIV transmission to humans.
Results
Vaccination induced anti-envelope antibodies, modest
CD4+ and CD8+ T-cell responses. One third of the vacci-
nated macaques were protected from SIVmac251 acquisi-
tion, whereas the remaining infected vaccinees progressed
to disease. Vaccine induced SIV mac251 specific T-and B-
cell responses were not different in protected or infected
animals. The sera of the animals protected had higher
avidity antibodies to the gp120 envelope protein, recog-
nized the variable envelope region V2, and reduced SIV-
mac251 infectivity in cells that express high level of a4b7,
suggesting a functional role to antibodies to V2.
Conclusion
The SIV mac251 infection macaque faithfully reproduces
results in humans, and is instrumental in the develop-
ment of more efficacious vaccines for HIV.
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